It Is Called Forward Looking BS
11. Between 2006 and 2016, Theralase also disclosed revenue projections for the TLC2000
(the“Revenue Projections”). The financial outlooks appeared in offering memoranda and other marketing materials provided to prospective investors and posted on the Internet, as well as in a post on Theralase’s Twitter feed. They ranged from $2.5 million 1 Dated November 20, 2006. - 4 - to $10 million in the first year of launch to $50 million to $60 million in the fifth year following launch of the TLC-2000. 12. Theralase also referred to five-year outlooks in its SEDAR filings (the “Growth Targets”). For example, in a news release dated August 16, 2012, Dumoulin-White stated that one aspect of the Company’s mandate was to build the TLT Division into a “$50 million annual recurring revenue model within the next 5 to 7 years.” Theralase’s Annual Information Forms (“AIF”) dated September 24, 2014 provided that “Theralase’s corporate mandate is to capture at least 1% of the therapeutic laser market, thus achieving annual revenues of >$50 million . . . within five years of launch” of the TLC-2000.